Last edition
News about "Biosimilars "
India's Pharma 2.0: Moving Beyond Generics to Innovation
For decades, India has been known as the “pharmacy of the world.” The country built this reputation on its strength in generics. Low-cost medicines from Indian companies reached millions across the globe. They helped make treatments affordable in developed and developing nations alike.
Biosimilars | 13/09/2025 | By Darshana
Sandoz Reports Strong H1 2025 Results, Accelerated Growth in Biosimilars and Generics
Sandoz has reported strong financial results for the first half of the financial year 2025, with the company’s net sales reaching USD 5.2 billion. Growth accelerated in the second quarter, driven by solid performance across both the generics and biosimilars businesses.
Biosimilars | 07/08/2025 | By Dineshwori | 154
Sandoz to Acquire Just-Evotec Biologics in USD 300 Million Deal
Sandoz has signed a non-binding term sheet with Evotec SE, paving the way for the potential acquisition of Just–Evotec Biologics EU SAS for approximately USD 300 million.
Biosimilars | 30/07/2025 | By Dineshwori | 108
Samsung Bioepis Partners with Harrow for US Commercialisation of Ophthalmology Biosimilars
Following the transition of commercial rights from Biogen back to Samsung Bioepis, Harrow will assume full responsibility for the commercialisation of both BYOOVIZ and OPUVIZ biosimilars in the US.
Biosimilars | 18/07/2025 | By Dineshwori
Sandoz Begins Construction Of USD 440 Million Biosimilars Production Facility In Slovenia
Sandoz is constructing a new facility in Slovenia to strengthen its European biosimilar hub and expand its global market presence.
Biosimilars | 10/07/2025 | By Dineshwori | 178
Global API Market Expected to Reach USD 422.8 Billion by 2034
The global Active Pharmaceutical Ingredients (API) market is projected to grow at a compound annual growth rate (CAGR) of 6.7 percent to an estimated USD 422.8 billion by 2034, according to a report.
Biosimilars | 09/07/2025 | By Dineshwori
Lupin Signs USD 50 million Deal with Zentiva to Commercialise Biosimilar Certolizumab Pegol Globally
Zentiva will be responsible for marketing and distribution of Lupin’s biosimilar Certolizumab Pegol outside the USA and Canada—primarily across Europe and the CIS (Commonwealth of Independent States) region.
Biosimilars | 09/07/2025 | By Dineshwori | 145
Bio-Thera Solutions, Tabuk Pharmaceutical Partner to Commercialise BAT2206 in Saudi Arabia
Bio-Thera Solutions Inc. has partnered with Tabuk Pharmaceutical Manufacturing Company, a fully-owned subsidiary of Astra Industrial Group, for BAT2206, its ustekinumab biosimilar.
Biosimilars | 26/12/2024 | By Abha | 450
Biocon Biologics' Report Offers Insights on Increasing Biosimilars Adoption in LMICs
Biocon Biologics commissioned the study, defined the methodology and collaborated with Clarivate to develop the final report.
Biosimilars | 09/10/2024 | By Aishwarya | 306
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy